首页> Neuropsychiatric disease and treatment> Aripiprazole Lauroxil: Development and Evidence-Based Review of a Long-Acting Injectable Atypical Antipsychotic for the Treatment of Schizophrenia.

Aripiprazole Lauroxil: Development and Evidence-Based Review of a Long-Acting Injectable Atypical Antipsychotic for the Treatment of Schizophrenia.

导出 OA

翻译打印收藏纠错

第一作者： Leslie,Citrome

第一单位： New York Medical College, Valhalla, NY, USA.

作者： Leslie,Citrome ^[1] ; Christoph U,Correll ^[2] ; Andrew J,Cutler ^[3] ; Martin,Dunbar ^[4] ; Amber R,Hoberg ^[5] ; Craig,Hopkinson ^[4] ; Gregory W,Mattingly ^[6] ; James A,McGrory ^[4] ; Bhaskar,Rege ^[4] ; Peter J,Weiden ^[7] ; David,McDonnell ^[8]

作者单位： New York Medical College, Valhalla, NY, USA. ^[1] Department of Psychiatry, The Zucker Hillside Hospital, Northwell Health, Glen Oaks, NY, USA.;Department of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA.;Center for Psychiatric Neuroscience, The Feinstein Institute for Medical Research, Northwell Health, New Hyde Park, NY, USA.;Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin Berlin, Berlin, Germany.;German Center for Mental Health (DZPG), Partner Site Berlin, Berlin, Germany. ^[2] Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY, USA.;Neuroscience Education Institute, Lakewood Ranch, FL, USA. ^[3] Alkermes, Inc, Waltham, MA, USA. ^[4] WellMed Medical Management, South Texas Medical Center, San Antonio, TX, USA. ^[5] Washington University School of Medicine, St. Louis, MO, USA.;Midwest Research Group, St. Louis, MO, USA. ^[6] Renaissance School of Medicine at Stony Brook University, Stony Brook, NY, USA. ^[7] Alkermes Pharma Ireland Ltd, Dublin, Ireland. ^[8]

关键词 dosing pharmacokinetics phase 3 clinical trials safety treatment efficacy treatment initiation

DOI 10.2147/NDT.S499367

PMID 40110113

发布时间 2025-03-20

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交